RedHill Biopharma Ltd. (RDHL) stock
Close on Nov 12, 2026Market cap $1.94MP/E –Yield –
RedHill Biopharma Ltd. saw revenue fall 96.4% to $286.00K over fiscal 2025. Free cash flow was -$9.66M. At the latest close the market valued the company at $1.94M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.94M
- P/E ratio
- –
- Price to sales
- 6.79
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -497.56%
Fundamentals
- Revenue
- $286.00K
- EPS, diluted
- $0.00
- Free cash flow
- -$9.66M
Trading
- Previous close
- $0.37
- Open
- $0.37
- Day's range
- $0.36 – $0.40
- Volume
- 71,629
- Average volume (20 days)
- 106,631
- Beta (5 years)
- 1.71
- 52-week range
- $0.37 – $1.60
- RSI (14 days)
- 34.6
- Volatility (1 year)
- 91.3%
- Relative volume
- 0.02×
- WACC
- 13.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RDHL | S&P 500 | Difference | RDHL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.6% | -2.7% | −25.9 pts | ||
| 3 months | -35.4% | -1.7% | −33.7 pts | ||
| Year to date | -63.0% | +11.9% | −74.9 pts | ||
| 1 year | -64.4% | +12.0% | −76.4 pts | ||
| 3 years | -95.0% | +78.2% | −173.2 pts | -63.2% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -84.9% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -64.5% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases RedHill Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About RedHill Biopharma
Pharmaceutical Preparations
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of pharmaceuticals for gastrointestinal diseases, infectious diseases, and oncology. The company commercializes Talicia, an FDA-approved delayed-release oral capsule indicated for the treatment of Helicobacter pylori infection in adults. It also develops a clinical-stage pipeline of therapeutic candidates, including opaganib and RHB-107, addressing viral infections, inflammatory conditions, and various cancers for adult patients and global healthcare markets.
Company profile, executives and historyRedHill Biopharma stock: common questions
What is RedHill Biopharma's stock price?
RDHL closed at $0.38 on Nov 12, 2026, up 4.13% on the day. Over the past 52 weeks it traded between $0.37 and $1.60.
What is RedHill Biopharma's market cap?
RedHill Biopharma was worth $1.94M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RDHL's P/E ratio?
RedHill Biopharma lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.
How much revenue does RedHill Biopharma make?
RedHill Biopharma reported revenue of $286.00K for fiscal 2025, down 96.4% from a year earlier.
Does RedHill Biopharma pay a dividend?
No. RedHill Biopharma has not paid a cash dividend over the last twelve months.
How has RDHL stock performed over the past year?
Including dividends, RDHL returned -64.4% over the past year, against +12.0% for the S&P 500.
Who are RedHill Biopharma's competitors?
Companies most similar to RedHill Biopharma by business, industry and size include XTLB, CANF, LIPO, HIND, RLYB.
See a number that looks wrong?